Dana-Farber Cancer Institute
The main purpose of this study is to field test and pilot an intervention called UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) that includes information about lymphoma survivorship and tools to improve quality of life and reduce lymphoma-related worries among lymphoma survivors.
This is a two phase pilot study to develop and pilot the UPLYFT (Understand and Prevail: Lymphoma Fear of Recurrence Therapy) program intervention that includes lymphoma survivorship information and acceptance and commitment therapy strategies to alleviate fear of cancer recurrence, reduce distress, and improve quality of life among lymphoma survivors. Phase 1 will be a two-part development process of the UPLYFT program based on interview feedback from lymphoma and mental health clinicians and then feedback from a six-person group of lymphoma survivors after participation in an UPLYFT program…
Inclusion Criteria: Lymphoma Survivors Phase 1 and 2: * Diagnosis of lymphoma (indolent non-Hodgkin lymphoma, aggressive non-Hodgkin lymphoma, or classic Hodgkin lymphoma) * Age ≥ 18 years * Interval of 3 months to 24 months from completion of first-line treatment * In complete remission after first line of treatment * Clinically significant FCR (score of ≥ 16 on the validated FCR Inventory-Severity Subscale \[FCRI-SS). * Access to computer (for videoconferencing) Lymphoma clinicians and mental health clinicians Phase 1: * Lymphoma clinicians ≥ 1 year from oncology fellowship completion OR…
One time, qualitative interview of clinicians for feedback on UPLYFT intervention
6 session of UPLYFT intervention with Lymphoma Survivors for feedback
6 session of UPLYFT intervention with Lymphoma Survivors
Arctuva estimate
Verify or correct the compensation shown for this listing.